Abstract: DNA dendrimers linked to both a targeting moiety and a siRNA which inhibits expression of Human antigen R (HuR), pharmaceutical compositions comprising the DNA dendrimers and methods of treatment and use employing the DNA dendrimers. Useful siRNA sequences are also disclosed.

Abstract: Compositions are disclosed which comprise a DNA dendrimer having one or more DNA sequences linked thereto, the DNA sequences comprising DNA sequences encoding a polypeptide or regulatory RNA linked to DNA sequences that regulate expression of the DNA sequences encoding a polypeptide or regulatory RNA to produce an RNA coding for the polypeptide or to produce the regulatory RNA. Also disclosed are methods for treating diseases and conditions of cells by delivering the dendrimers to the cells, with subsequent expression of the encoded polypeptide or regulatory RNA.

Abstract: DNA dendrimer linked to both a targeting moiety and a siRNA which inhibits expression of Human antigen R (HuR), pharmaceutical compositions comprising the DNA dendrimers and methods of treatment and use employing the DNA dendrimers. Useful siRNA sequences are also disclosed.

Abstract: Compositions are disclosed which comprise a DNA dendrimer having one or more DNA sequences linked thereto, the DNA sequences comprising DNA sequences encoding a polypeptide or regulatory RNA linked to DNA sequences that regulate expression of the DNA sequences encoding a polypeptide or regulatory RNA to produce an RNA coding for the polypeptide or to produce the regulatory RNA. Also disclosed are methods for treating diseases and conditions of cells by delivering the dendrimers to the cells, with subsequent expression of the encoded polypeptide or regulatory RNA.

Abstract: Compositions are disclosed which comprise a DNA dendrimer having one or more DNA sequences linked thereto, the DNA sequences comprising DNA sequences encoding a polypeptide or regulatory RNA linked to DNA sequences that regulate expression of the DNA sequences encoding a polypeptide or regulatory RNA to produce an RNA coding for the polypeptide or to produce the regulatory RNA. Also disclosed are methods for treating diseases and conditions of cells by delivering the dendrimers to the cells, with subsequent expression of the encoded polypeptide or regulatory RNA.

Abstract: The present invention provides compositions and methods for treatment of conditions and diseases associated with excessive or inappropriate noncancerous tissue growth. In certain embodiments of the invention the compositions and methods are used for treatment of benign prostatic hyperplasia. In certain embodiments of the invention the composition comprises a tissue-selective delivery vehicle. In certain embodiments of the invention the compositions comprise an expression vector that encodes a cytotoxic polypeptide, wherein expression of the cytotoxic polypeptide is under control of a prostate-specific regulatory element. In certain embodiments of the invention the compositions comprise an expression vector in which expression of a recombinase is under control of a prostate-specific regulatory element, and a recombination event mediated by the recombinase is required for expression of the cytotoxic polypeptide.

Abstract: Aspects of the invention relate to nucleic acids molecules that are useful for specifically destroying selected cells, tissues, or organs. Aspects of the invention are useful for treating diseases (e.g., cancer) that affect specific cells, tissues, or organs.

Abstract: The present invention relates to the use of an inducible genetic recombination system to target expression of a toxin to cancer cells and to hereby prevent the recurrence of particular tumors. The present invention also relates to the use of an inducible genetic recombination system to target expression of diphtheria toxin to androgen-independent cancer cells following androgen ablation therapy and to thereby prevent the development of recurrent prostatic tumors.

Abstract: The invention features a transgenic mammal encoding a chimeric ornithine decarboxylase gene, which transgenic mammal exhibits phenotypic abnormalities. The invention also includes a chimeric transgene comprising ornithine decarboxylase.